Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEPRE Trial
2024-516874-31-00Phase 3Authorised
- Sponsor
- Ospedali Galliera
- Start
- Dec 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial in low-grade serous ovarian carcinoma (LGSOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Letrozole monotherapy with Carboplatin + paclitaxel chemotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Dec 2024; status: authorised.
02
Drugs
ribociclib + letrozolecarboplatinpaclitaxel
03
Conditions
low-grade serous ovarian carcinoma (LGSOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-516874-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516874-31-00.